2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N6786
    Ochratoxin B 4825-86-9 99.90%
    Ochratoxin B is an orally active secondary metabolite of Aspergillus ochraceus and non-chlorinated analog of the mycotoxin Ochratoxin A. Ochratoxin B reduces the toxic effects of Ochratoxin A (HY-N6788). Ochratoxin B inhibits cell division. Ochratoxin B causes craniofacial malformations in Xenopus laevis embryos.
    Ochratoxin B
  • HY-N6962
    α-Spinasterol 481-18-5 99.90%
    α-Spinasterol is an orally taken antagonist of transient receptor potential vanilloid 1 ( TRPV1), and it's also an inhibitor of COX-1 and COX-2, with IC50 values of 16.17 μM and 7.76 μM, respectively. α-Spinasterol exhibits antibacterial, anti-inflammatory, antidepressant, and antioxidant effects, has the ability to cross the blood-brain barrier, and can improve diabetes in mice.
    α-Spinasterol
  • HY-N6963
    Choerospondin 81202-36-0 99.87%
    Choerospondin is a flavanone isolated from the bark of Choerospondias axillaris.
    Choerospondin
  • HY-N7110
    6-Hydroxyflavone 6665-83-4 99.92%
    6-Hydroxyflavone is an orally effective flavonoid compound. 6-Hydroxyflavone can inhibit LPS (HY-D1056) -induced NO production and has anti-inflammatory effects. 6-Hydroxyflavone promotes osteoblast differentiation by activating AKT, ERK 1/2 and JNK signaling pathways. 6-Hydroxyflavone has an inhibitory effect on bovine hemoglobin (BHb) glycosylation. 6-Hydroxyflavone has a kidney protective effect. In addition, 6-Hydroxyflavone enhances GABA-induced current through the Benzodiazepine sites of γ-aminobutyric acid (GABAA) receptors. 6-Hydroxyflavone shows a clear preference for α2 - and α3 - subtypes, which play an anti-anxiety role.
    6-Hydroxyflavone
  • HY-N7393
    Isomalt 64519-82-0 99.99%
    Isomalt (Palatinitol), a well-tolerated, non-toxic polyol and a protein-stabilizing excipient, stabilizes lactate dehydrogenase (LDH) moderately during freeze-drying, and performs better during storage. Isomalt is traditionally used as a sweetening agent in the food industry and as a tabletting excipient for pharmaceutical purposes.
    Isomalt
  • HY-P0243
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon 86073-88-3 98.69%
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon (Salmon GnRH) is the hypophysiotropic decapeptide synthesized in the hypothalamus that plays a crucial role in the control of reproductive functions.
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon
  • HY-P1015
    VIP(Guinea pig) 96886-24-7 98.66%
    VIP Guinea pig (Vasoactive intestinal peptide), a trophic and mitogenic factor, stimulates growth in whole cultured embryos. VIP Guinea pig functions as a simple gastrointestinal hormone and suggest a possible neurotransmitter function.
    VIP(Guinea pig)
  • HY-P1096
    A71623 130408-77-4 99.34%
    A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively.
    A71623
  • HY-P2768
    Leucine dehydrogenase, Microorganism 9082-71-7
    Leucine dehydrogenase, Microorganism (EC 1.4.1.9) can be purified from Bacillus spheroides. Leucine dehydrogenase catalyzed the oxidative deamination of L-leucine, L-valine, L-isoleucine, L-norvaline, L-alpha-aminobutyrate, and L-norleucine, and the reductive amination of their keto analogues.
    Leucine dehydrogenase, Microorganism
  • HY-Y0057
    NSC 13138 486-74-8 99.58%
    NSC 13138 is an endogenous metabolite.
    NSC 13138
  • HY-100277
    Mifobate 76541-72-5 99.85%
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects.
    Mifobate
  • HY-100589
    Isepamicin sulfate 67814-76-0 98.0%
    Isepamicin sulfate (Sch 21420 sulfate) is a broad-spectrum aminoglycoside antibiotic. Isepamicin sulfate has considerable antimicrobial activity against some Gram-negative non-fermenting bacteria that are highly resistant to antibiotics. Isepamicin sulfate inhibits writhing reactions induced by Acetic acid (HY-Y0319), regulates vascular blood flow and blood pressure, and inhibits spontaneous uterine movements. Isepamicin sulfate has antidiuretic and blood sugar-raising effects. Isepamicin sulfate can be used in seizure research.
    Isepamicin sulfate
  • HY-101051
    2-TEDC 132465-10-2 99.58%
    2-TEDC is a potent inhibitor of 5-, 12-, and 15-lipoxygenase with IC50 values of 0.09 μM, 0.013 μM and 0.5 μM, respectively. 2-TEDC can be used for the research of atheroscrelosi.
    2-TEDC
  • HY-101548
    OGT-IN-1 371215-02-0 98.14%
    OGT-IN-1 (Compound 5) is a potent OGT inhibitor. OGT-IN-1 inhibits sOGT and ncOGT with IC50s of 27 and 10 μM, respectively.
    OGT-IN-1
  • HY-103391
    Qc1 403718-45-6 ≥98.0%
    Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease.
    Qc1
  • HY-108557
    TCS 2510 346673-06-1 ≥98.0%
    TCS 2510 is a selective EP4 agonist. TCS 2510 can be used for the research of metabolic diseases.
    TCS 2510
  • HY-108795
    Albiglutide fragment 224638-84-0 99.86%
    Albiglutide fragment (GLP-1 (7-36) analog) is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies.
    Albiglutide fragment
  • HY-108844
    Rasburicase 134774-45-1
    Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout.
    Rasburicase
  • HY-110181
    M8-B 883976-12-3 99.74%
    M8-B is a potent transient receptor potential melastatin-8 (TRPM8) antagonist. M8-B blocks cold-induced and TRPM8-agonist-induced activation TRPM8 channels. M8-B decreases deep body temperature (Tb).
    M8-B
  • HY-110206
    AM6545 1245626-05-4 99.32%
    AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (Ki=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications.
    AM6545
Cat. No. Product Name / Synonyms Application Reactivity